<info type="GeneOrGeneProduct">centrosomal protein 55</info> is associated with unfavorable prognosis and <info type="DiseaseOrPhenotypicFeature">tumor invasion</info> in <info type="DiseaseOrPhenotypicFeature">epithelial ovarian carcinoma</info>.

<info type="GeneOrGeneProduct">Centrosomal protein 55</info> (<info type="GeneOrGeneProduct">CEP55</info>) is a <info type="GeneOrGeneProduct">cell cycle regulator</info> implicated in development of certain <info type="DiseaseOrPhenotypicFeature">cancers</info>. However, characteristics of <info type="GeneOrGeneProduct">CEP55</info> expression and its clinical/prognostic significance are unclear in <info type="OrganismTaxon">human</info> <info type="DiseaseOrPhenotypicFeature">epithelial ovarian carcinoma</info> (<info type="GeneOrGeneProduct">EOC</info>). Therefore, we investigated the expression and clinicopathological significance of <info type="GeneOrGeneProduct">CEP55</info> in patients with <info type="GeneOrGeneProduct">EOC</info> and its role in regulating <info type="DiseaseOrPhenotypicFeature">invasion</info> and <info type="DiseaseOrPhenotypicFeature">metastasis</info> of <info type="CellLine">ovarian cell lines</info>. <info type="GeneOrGeneProduct">CEP55</info> mRNA and protein expression levels were detected by <info type="GeneOrGeneProduct">quantitative real-time PCR</info> (<info type="GeneOrGeneProduct">qRT-PCR</info>), <info type="GeneOrGeneProduct">Western blotting</info>, and <info type="GeneOrGeneProduct">immunohistochemistry</info> (<info type="GeneOrGeneProduct">IHC</info>). Potential associations of <info type="GeneOrGeneProduct">CEP55</info> expression scores with clinical parameters and patient survival were evaluated. <info type="GeneOrGeneProduct">CEP55</info> function was investigated further using <info type="GeneOrGeneProduct">RNA interference</info>, <info type="GeneOrGeneProduct">wound healing assay</info>, <info type="GeneOrGeneProduct">transwell assay</info>, <info type="GeneOrGeneProduct">immunofluorescence analysis</info>, <info type="GeneOrGeneProduct">qRT-PCR</info>, and <info type="GeneOrGeneProduct">Western blotting</info>. <info type="GeneOrGeneProduct">CEP55</info> was significantly upregulated in <info type="DiseaseOrPhenotypicFeature">ovarian cancer cell lines</info> and lesions compared with normal cells and adjacent noncancerous <info type="OrganismTaxon">ovarian tissues</info>. In the <info type="SequenceVariant">213</info> <info type="DiseaseOrPhenotypicFeature">EOC</info> samples, <info type="GeneOrGeneProduct">CEP55</info> protein levels were positively correlated with clinical stage (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>), lymph node metastasis (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>), intraperitoneal metastasis (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>), tumor recurrence (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>), differentiation grade (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>), residual tumor size (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>), ascites see tumor cells (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">= 0.020</info>), and serum <info type="GeneOrGeneProduct">CA153</info> level (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>). Moreover, patients with aberrant <info type="GeneOrGeneProduct">CEP55</info> protein expression showed tendencies to receive <info type="ChemicalEntity">neoadjuvant chemotherapy</info> (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">< 0.001</info>) and <info type="ChemicalEntity">cytoreductive surgery</info> (<info type="GeneOrGeneProduct">P</info> <info type="SequenceVariant">= 0.020</info>). By contrast, no significant correlation was detected between the protein levels and patient age, histological type, or serum <info type="GeneOrGeneProduct">CA125</info>, <info type="GeneOrGeneProduct">CA199</info>, <info type="GeneOrGeneProduct">CA724</info>, <info type="GeneOrGeneProduct">NSE</info>, <info type="GeneOrGeneProduct">CEA</info>, and <info type="GeneOrGeneProduct">b-HCG</info> levels. Patients with high <info type="GeneOrGeneProduct">CEP55</info> protein expression had shorter overall survival and disease-free survival compared with those with low <info type="GeneOrGeneProduct">CEP55</info> expression. Multivariate analysis implicated <info type="GeneOrGeneProduct">CEP55</info> as an independent prognostic indicator for <info type="DiseaseOrPhenotypicFeature">EOC</info> patients. Additionally, downregulation of <info type="GeneOrGeneProduct">CEP55</info> in <info type="DiseaseOrPhenotypicFeature">ovarian cancer cells</info> remarkably inhibited cellular motility and invasion. Aberrant <info type="GeneOrGeneProduct">CEP55</info> expression may predict unfavorable clinical outcomes in <info type="DiseaseOrPhenotypicFeature">EOC</info> patients and play an important role in regulating invasion in <info type="DiseaseOrPhenotypicFeature">ovarian cancer cells</info>. Thus, <info type="GeneOrGeneProduct">CEP55</info> may serve as a prognostic marker and therapeutic target for <info type="DiseaseOrPhenotypicFeature">EOC</info>.